| DVN |
Report |
Adjusted EPS |
BEAT |
pred ~$1.42 vs. cons ~$1.30 |
MEDIUM |
| DVN |
Report |
Free cash flow |
BEAT |
pred ~$1.3B vs. cons ~$1.15B |
MEDIUM |
| DVN |
Report |
Total production (first combined quarter, ~55 days of Coterra) |
IN-LINE |
pred ~1.16 MMBoe/d vs. cons ~1.15 MMBoe/d |
LOW |
| DVN |
Guide |
FY2026 production guide (vs June combined outlook) |
UNCHANGED |
guide ~1.38 MMBoe/d vs. cons ~1.38 MMBoe/d (FY2026) |
MEDIUM |
| DVN |
Guide |
FY2026 capital budget |
UNCHANGED |
guide ~$4.9B vs. cons ~$4.9B (FY2026) |
MEDIUM |
| DVN |
Guide |
Merger synergy target (pull-forward/raise) |
BETTER |
guide ~$1.1-1.2B vs. cons $1.0B (annual run-rate by YE2027) |
MEDIUM |
| DVN |
Guide |
Shareholder-return framework / buyback pace under new authorization |
BETTER |
guide ~$8.0B buyback + ~70% FCF payout vs. cons ~$8.0B auth at ~50-60% payout (2026) |
LOW |
| DVN |
Guide |
Portfolio review / Marcellus & non-core divestitures (TOMS/Kimmeridge pressure) |
UNKNOWN |
guide ~$0 announced vs. cons ~$2B+ expected proceeds (2026-27) |
MEDIUM |
| DVN |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| DVN |
Return |
5-day cumulative residual |
+0.3% (FADE) |
Headline beat is largely discounted after CVX/XOM/FANG blowouts and is backward-looking on peak Iran-war oil realizations; with oil rolling over ~5% on US-Iran talk hopes, out-quarter deck assumptions and estimates get trimmed even on a beat. Absent a concrete divestiture/portfolio decision, the activist overhang (TOMS/Kimmeridge) and merger-accounting noise cap follow-through, so an initial synergy-driven pop fades back toward flat. |
LOW |